Sm. Horowitz et al., PHARMACOLOGICAL INHIBITION OF PARTICULATE-INDUCED BONE-RESORPTION, Journal of biomedical materials research, 31(1), 1996, pp. 91-96
In this study, a rat calvaria/macrophage co-culture model was used to
study the effects of various agents upon bone resorption induced by ma
crophage exposure to bone cement particles. The experimental group con
sisted of calvaria bone disks set in tissue culture medium on stainles
s-steel platforms into wells with macrophages adherent to the bottom w
hich are exposed to the particles. Tumor necrosis factor a (TNF-alpha)
, prostaglandin E(2) (PGE(2)), and calcium 45 (Ca-45) were released in
significant amounts in this system. Interleukin 1 alpha (IL-1 alpha)
was not detected. Indomethacin inhibited the production of PGE(2) but
did not affect TNF release or inhibit the release of Ca-45. Anti-TNF a
ntibody neutralized the presence of TNF to undetectable levels, but di
d not affect PGE(2) release or inhibit Ca-45 release. The addition of
calcitonin did not inhibit Ca-45 release by calvaria. In contrast, the
addition of disodium pamidronate, a member of the bisphosphonate fami
ly, was effective in inhibiting the release of Ca-45 even after 96 h o
f incubation. In prior studies, incubation of calvaria in conditioned
medium from macrophages exposed to cement particles led to resorption
through a mechanism which is dependent upon TNF production by macropha
ges, and PGE(2) production by cells in bone. In this two-way system, i
n which macrophages and cells in bone are allowed to interact, this de
pendency was no longer evident. Pamidronate was the only agent tested
which suppressed the increase in bone resorption associated with macro
phage exposure to bone cement particles to levels which were not signi
ficantly different from unexposed calvaria. By delaying or preventing
bone resorption associated with macrophage exposure to bone cement par
ticles, bisphosphonates may have a clinical role in cemented joint art
hroplasty by decreasing the rate or incidence of aseptic loosening and
prolonging implant longevity. (C) 1996 John Wiley & Sons, Inc.